CoChat

The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression: A 12-Week Double-Blind, Randomized Controlled Trial

Lee, Sheng-Yu, Chen, Shiou-Lan, Chang, Yun-Hsuan, Chen, Po See, Huang, San-Yuan, Tzeng, Nian-Sheng, Wang, Yu-Shan, Wang, Liang-Jen, Lee, I Hui, Wang, Tzu-Yun, Yeh, Tzung Lieh, Yang, Yen Kuang, Hong, Jau-Shyong, Lu, Ru-Band · 2014 · Journal of Clinical Psychopharmacology
Cited by 45

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Memantine, a noncompetitive N-methyl-d-aspartate receptor antagonist with a mood-stabilizing effect, and an association between bipolar disorder and proinflammatory cytokine levels have been reported. Whether adding-on memantine would reduce cytokine levels and is more effective than valproic acid (VPA) alone in bipolar II disorder was investigated. A randomized, double-blind, controlled, 12-week study was conducted. Patients undergoing regular VPA treatments were randomly assigned to a group: VPA + memantine (5 mg/d) (n = 106) or VPA + placebo (n = 108). The Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were used to evaluate clinical response. Symptom severity, plasma tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), IL-8, and IL-1 levels were examined during weeks 0, 1, 2, 4, 8, and 12. To adjust within-subject dependence over repeated assessments, multiple linear regressions with generalized estimating equation methods were used to examine the therapeutic effect. Tumor necrosis factor α levels were significantly lower in the VPA + memantine group than in the VPA + placebo group (P = 0.013). Posttreatment HDRS and YMRS scores decreased significantly in both groups, but not significant, nor was the other between-group cytokine level difference pretreatment and posttreatment. The HDRS score changes were significantly associated with IL-6 (P = 0.012) and IL-1 (P = 0.005) level changes and changes in YMRS score changes with TNF-α (P = 0.005) level changes. Treating bipolar II depression with VPA + memantine may improve the plasma TNF-α level. However, adding-on memantine may not improve clinical symptoms or cytokine levels other than TNF-α. Clinical symptoms may be correlated with certain cytokines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000000109

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 44

  1. Angst, 2003, Recurrence of bipolar disorders and major depression. A life-long perspective., Eur Arch Psychiatry Clin Neurosci, 253, 236, 10.1007/s00406-003-0437-2 · DOI · Paper page
  2. Benazzi, 2001, Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients., J Affect Disord, 66, 13, 10.1016/S0165-0327(99)00038-5 · DOI
  3. Benazzi, 2003, Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania., J Affect Disord, 73, 33, 10.1016/S0165-0327(02)00327-0 · DOI · Paper page
  4. Angst, 2007, The bipolar spectrum., Br J Psychiatry, 190, 189, 10.1192/bjp.bp.106.030957 · DOI · Paper page
  5. Spence, 2011, Bad medicine: bipolar II disorder., BMJ, 342, d2767, 10.1136/bmj.d2767 · DOI
  6. Angst, 2003, Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania., J Affect Disord, 73, 133, 10.1016/S0165-0327(02)00322-1 · DOI · Paper page
  7. Merikangas, 2012, The true prevalence of bipolar II disorder., Curr Opin Psychiatry, 25, 19, 10.1097/YCO.0b013e32834de3de · DOI · Paper page
  8. Pallanti, 1999, Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder., Am J Psychiatry, 156, 1094, 10.1176/ajp.156.7.1094 · DOI · Paper page
  9. Vieta, 1997, Differential features between bipolar I and bipolar II disorder., Compr Psychiatry, 38, 98, 10.1016/S0010-440X(97)90088-2 · DOI · Paper page
  10. Goldstein, 2009, Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature., J Clin Psychiatry, 70, 1078, 10.4088/JCP.08r04505 · DOI · Paper page
  11. Breunis, 2003, High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder., Biol Psychiatry, 53, 157, 10.1016/S0006-3223(02)01452-X · DOI
  12. Knijff, 2007, An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment., Bipolar Disord, 9, 743, 10.1111/j.1399-5618.2007.00444.x · DOI · Paper page
  13. Soderlund, 2011, Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder., J Psychiatry Neurosci, 36, 114, 10.1503/jpn.100080 · DOI · Paper page
  14. Knijff, 2006, Monocyte-derived dendritic cells in bipolar disorder., Biol Psychiatry, 59, 317, 10.1016/j.biopsych.2005.06.041 · DOI
  15. Bosetti, 2002, Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain., Mol Psychiatry, 7, 845, 10.1038/sj.mp.4001111 · DOI
  16. Rapaport, 2001, The effects of lithium on ex vivo cytokine production., Biol Psychiatry, 50, 217, 10.1016/S0006-3223(01)01144-1 · DOI
  17. Kowatch, 2005, Treatment guidelines for children and adolescents with bipolar disorder., J Am Acad Child Adolesc Psychiatry, 44, 213, 10.1097/00004583-200503000-00006 · DOI · Paper page
  18. Yatham, 2009, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009., Bipolar Disord, 11, 225, 10.1111/j.1399-5618.2009.00672.x · DOI · Paper page
  19. Bauer, 2002, Bipolar disorder., Ment Health Serv Res, 4, 225, 10.1023/A:1020968616616 · DOI
  20. Beyer, 2002, Volumetric brain imaging findings in mood disorders., Bipolar Disord, 4, 89, 10.1034/j.1399-5618.2002.01157.x · DOI · Paper page
  21. Wu, 2009, Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation., Neuropsychopharmacology, 34, 2344, 10.1038/npp.2009.64 · DOI · Paper page
  22. Chipana, 2008, Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents., Neuropharmacology, 54, 1254, 10.1016/j.neuropharm.2008.04.003 · DOI
  23. Popik, 1996, The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence., Pharmacol Biochem Behav, 53, 791, 10.1016/0091-3057(95)02163-9 · DOI
  24. Ribeiro Do Couto, 2004, Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice., Prog Neuropsychopharmacol Biol Psychiatry, 28, 1035, 10.1016/j.pnpbp.2004.05.038 · DOI
  25. Chen, 2012, Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats., J Neuroimmune Pharmacol, 7, 444, 10.1007/s11481-011-9337-9 · DOI
  26. Parsons, 1999, Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonista review of preclinical data., Neuropharmacology, 38, 735, 10.1016/S0028-3908(99)00019-2 · DOI · Paper page
  27. Endicott, 1978, A diagnostic interview: the schedule for affective disorders and schizophrenia., Arch Gen Psychiatry, 35, 837, 10.1001/archpsyc.1978.01770310043002 · DOI · Paper page
  28. Huang, 2004, Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence., Alcohol Clin Exp Res, 28, 374, 10.1097/01.ALC.0000117832.62901.61 · DOI · Paper page
  29. Akiskal, 1977, Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group., Am J Psychiatry, 134, 1227, 10.1176/ajp.134.11.1227 · DOI · Paper page
  30. Akiskal, 1979, Differentiation of primary affective illness from situational, symptomatic, and secondary depressions., Arch Gen Psychiatry, 36, 635, 10.1001/archpsyc.1979.01780060025002 · DOI · Paper page
  31. Angst, 1998, The emerging epidemiology of hypomania and bipolar II disorder., J Affect Disord, 50, 143, 10.1016/S0165-0327(98)00142-6 · DOI · Paper page
  32. Hamilton, 1960, A rating scale for depression., J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  33. Hamilton, 1967, Development of a rating scale for primary depressive illness., Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x · DOI · Paper page
  34. Young, 1978, A rating scale for mania: reliability, validity and sensitivity., Br J Psychiatry, 133, 429, 10.1192/bjp.133.5.429 · DOI · Paper page
  35. Zeger, 1988, Models for longitudinal data: a generalized estimating equation approach., Biometrics, 44, 1049, 10.2307/2531734 · DOI · Paper page
  36. Bhardwaj, 2003, Receptor-mediated choreography of life and death., J Clin Immunol, 23, 317, 10.1023/A:1025319031417 · DOI
  37. Kapczinski, 2009, The potential use of biomarkers as an adjunctive tool for staging bipolar disorder., Prog Neuropsychopharmacol Biol Psychiatry, 33, 1366, 10.1016/j.pnpbp.2009.07.027 · DOI · Paper page
  38. Quan, 2011, Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model., Neuroscience, 182, 88, 10.1016/j.neuroscience.2011.03.026 · DOI
  39. Rogoz, 2002, Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats., Neuropharmacology, 42, 1024, 10.1016/S0028-3908(02)00055-2 · DOI · Paper page
  40. Koukopoulos, 2012, The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial., J Affect Disord, 136, 163, 10.1016/j.jad.2011.09.040 · DOI
  41. Muhonen, 2008, Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence., J Clin Psychiatry, 69, 392, 10.4088/JCP.v69n0308 · DOI · Paper page
  42. Zdanys, 2008, A systematic review of off-label uses of memantine for psychiatric disorders., Prog Neuropsychopharmacol Biol Psychiatry, 32, 1362, 10.1016/j.pnpbp.2008.01.008 · DOI
  43. Goldberg, 1998, Association of recurrent suicidal ideation with nonremission from acute mixed mania., Am J Psychiatry, 155, 1753, 10.1176/ajp.155.12.1753 · DOI · Paper page
  44. Pan, 1999, Penetration of neurotrophins and cytokines across the blood-brainblood-spinal cord barrier., Adv Drug Deliv Rev, 36, 291, 10.1016/S0169-409X(98)00086-6 · DOI

Cited by

See all 45

Metadata

Authors
Lee, S.-Y., Chen, S.-L., Chang, Y.-H., Chen, P. S., Huang, S.-Y., Tzeng, N.-S., Wang, Y.-S., Wang, L.-J., Lee, I. H., Wang, T.-Y., Yeh, T. L., Yang, Y. K., Hong, J.-S., & Lu, R.-B.
Venue
Journal of Clinical Psychopharmacology
Published
2014-06
Volume
34
Issue
3
Pages
337-343
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1965692095
Cited by
45
References
14
FWCI
3.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression: A 12-Week Double-Blind, Randomized Controlled Trial. https://app.cochat.ai/papers/10.1097/jcp.0000000000000109
The paper
Lee, S.-Y., Chen, S.-L., Chang, Y.-H., Chen, P. S., Huang, S.-Y., Tzeng, N.-S., Wang, Y.-S., Wang, L.-J., Lee, I. H., Wang, T.-Y., Yeh, T. L., Yang, Y. K., Hong, J.-S., & Lu, R.-B. (2014). The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression: A 12-Week Double-Blind, Randomized Controlled Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.